Cytotoxic purine nucleoside analogues bind to A 1, A 2A, and A 3 adenosine receptors

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 5, 2012, Pages 519-525

  Jensen, Kyle ^a   Johnson, L'Aurelle A ^a,b,c   Jacobson, Pamala A ^a,b,c   Kachler, Sonja ^d   Kirstein, Mark N ^a   Lamba, Jatinder ^a   Klotz, Karl Norbert ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Division of Pediatric Epidemiology and Clinical Research   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

A 1, A 2A, A 2B, A 3 ligands; Adenosine receptors; Cladribine; Clofarabine; Fludarabine; Purine analogues

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENYLATE CYCLASE; CLADRIBINE; CLOFARABINE; CYTARABINE; FLUDARABINE; GEMCITABINE; PURINE NUCLEOSIDE DERIVATIVE; RADIOLIGAND;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CHINESE HAMSTER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; FEMALE; NONHUMAN; PROTEIN PROTEIN INTERACTION;

ADENINE NUCLEOTIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BINDING, COMPETITIVE; CHO CELLS; CLADRIBINE; CRICETINAE; CRICETULUS; CYTOTOXINS; HUMANS; PURINERGIC P1 RECEPTOR AGONISTS; RADIOLIGAND ASSAY; RECEPTORS, PURINERGIC P1; VIDARABINE;

EID: 84862881933     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0719-6     Document Type: Article

References (40)

1. Adjei AA, Dagnino L, Wong MM, Paterson AR (1992) Protection against fludarabine neurotoxicity in leukemic mice by the nucleo- side transport inhibitor nitrobenzylthioinosine. Cancer Chemother Pharmacol 31:71-75
2. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE (2003) Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102:1915-1919 (Pubitemid 37022593)
3. Beitinjaneh AM, McKinney AM, Cao Q, Weisdorf DJ (2011) Toxic leukoencephalopathy following fludarabine-associated hemato- poietic cell transplantation. Biol Blood Marrow Transplant 17:300-308
4. Cheson BD, Vena DA, Foss FM, Sorensen JM (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12:2216-2228 (Pubitemid 24356042)
5. Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225-1228 (Pubitemid 16004240)
6. Cunha RA (2005) Neuroprotection by adenosine in the brain: from A (1) receptor activation to A (2A) receptor blockade. Purinergic Signal 1:111-134 (Pubitemid 40466898)
7. de Mendonca A, Sebastiao AM, Ribeiro JA (2000) Adenosine: does it have a neuroprotective role after all? Brain Res Brain Res Rev 33:258-274
8. Ding X, Herzlich AA, Bishop R, Tuo J, Chan CC (2008) Ocular toxicity of fludarabine: a purine analog. Expert Rev Ophthalmol 3:97-109 (Pubitemid 351982412)
9. Dunwiddie TV, Masino SA (2001) The role and regulation ofadenosine in the central nervous system. Annu Rev Neurosci 24:31-55 (Pubitemid 32695222)
10. Faderl S, Gandhi V, Keating MJ, Jeha S, PlunkettW, Kantarjian HM (2005) The role of clofarabine in hematologic and solid malignancies- development of a next-generation nucleoside analog. Cancer 103:1985-1995 (Pubitemid 40605104)
11. Franchetti P, Cappelacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (2009) N-Cycloalkyl- andN-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. J Med Chem 52:2393-2406
12. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM (2005) Adenosine and brain function. Int Rev Neurobiol 63:191-270 (Pubitemid 43631262)
13. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA (2008) The A3 adenosine receptor: an enigmatic player in cell biology Pharmacol Ther 117:123-140 (Pubitemid 350192673)
14. Hentosh P, Peffley DM (2010) The cladribine conundrum: deciphering the drug's mechanism of action. Expert Opin Drug Metab Toxicol 6:75-81
15. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264 (Pubitemid 43336037)
16. Klotz KN (2000) Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol 362:382-391
17. Klotz KN, Cristalli G, Grifantini M, Vittori S, Lohse MJ (1985) Photo-affinity labeling of A1-adenosine receptors. J Biol Chem 260:14659-14664
18. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998) Comparative pharmacology of human adenosine recep-tor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1-9 (Pubitemid 28085115)
19. Lindemalm S, Liliemark J, Larsson BS, Albertioni F (1999) Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study. MedOncol 16:239-244 (Pubitemid 30055712)
20. Linden J (2005) Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67:1385-1387 (Pubitemid 40594134)
21. Long-Boyle J, Huang J, Rydholm N, Smith A, Orchard P, Tolar J, Jacobson P (2011a) Pharmacokinetics ofclofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. J Clin Pharmacol 51:679-686
22. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA (2011b) High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 46:20-26
23. Lorenzen A, Lang H, Schwabe U (1998) Activation of various subtypes of G-protein alpha subunits by partial agonists of the adenosine A1 receptor Biochem Pharmacol 56:1287-1293 (Pubitemid 28511266)
24. Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urbano-Ispizua A, Bargay J, Rayon C, Leon A, Sarra J, Odriozola J, Conde JG, Sierra J, San Miguel J, ALLOPBSCT Subcommittee of the Spanish Group for Haematopoietic Transplantation (GETH), Group GEL-TAMO (2001) Allogeneic peripheral blood stem cell trans-plantation with reduced-intensity conditioning: results of a prospec-tive multicentre study. Br J Haematol 115:653-659 (Pubitemid 34015658)
25. Merkel DE, Griffin NL, Kagan-Hallet K, Von HoffDD (1986) Central nervous system toxicity with fludarabine. Cancer Treat Rep 70:1449-1450 (Pubitemid 17005130)
26. Picano E, Abbracchio MP (2000) Adenosine, the imperfect en- dogenous anti-ischemic cardio-neuroprotector. Brain Res Bull 52:75-82 (Pubitemid 30259260)
27. Priebe T, Platsoucas CD, Nelson JA (1990) Adenosine receptors and modulation of natural killer cell activity by purine nucleosides. Cancer Res 50:4328-4331 (Pubitemid 20225673)
28. Ralevic V Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492 (Pubitemid 28477681)
29. Ribeiro JA, Sebastiao AM, de Mendonca A (2002) Adenosine recep- tors in the nervous system: pathophysiological implications. Prog Neurobiol 68:377-392 (Pubitemid 36165128)
30. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP (2001) Acute left ventricular failure following melphalan and fludarabine con- ditioning. Bone Marrow Transplant 28:101-103 (Pubitemid 32707626)
31. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P (2005) Purine nucleoside analogues for the treatment ofhemato- logical malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 5:421-444 (Pubitemid 41178983)
32. Schwabe U, Trost T (1980) Characterization ofadenosine receptors in rat brain by (-)[ H]N -phenylisopropyladenosine. Naunyn Schmiedebergs Arch Pharmacol 313:179-187 (Pubitemid 10010819)
33. Sebastiao AM, Ribeiro JA (2009) Adenosine receptors and the central nervous system. Handb Exp Pharmacol 193:471-534
34. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia- inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657-682 (Pubitemid 38680437)
35. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW (1986) Fludar- abine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 46:5953-5958 (Pubitemid 17178010)
36. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R, Sossman J (2003) Regimen-related toxicity after fludarabine- melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 32:471-476 (Pubitemid 37160961)
37. Vasova I, Penka M, Hajek R, Mayer J, Krahulcova E (1997) A new purine analog in the treatment of hematologic malignancy I. Fludarabine. Vnitr Lek 43:45-50 (Pubitemid 27166144)
38. Von HoffDD (1990) Phase I clinical trials with fludarabine phosphate. Semin Oncol 17:33-38 (Pubitemid 20356426)
39. Warrell RP Jr, Berman E (1986) Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79 (Pubitemid 16155964)
40. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F (2009) Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 78:1351-1359